71 results about "Helicobacter Infections" patented technology

The present invention concerns polymer particle vaccine delivery systems in which a water insoluble protein antigen, e.g. a lipidated HpaA protein, is incorporated with particles comprising a polymer matrix. The present invention also concerns a method for incorporating such a water insoluble protein antigen with a polymer matrix in order to produce a polymer particle vaccine delivery system. In addition, the invention also provides a vaccine composition comprising the polymer particle delivery system. The vaccine can be used to treat and / or reduce the risk of for example Helicobacter infection.

This disclosure demonstrates a novel therapy immunological approach using polyamine-based therapy (PBT) for relieving tumor-induced suppression of the patient's immune system. The demonstration of the pharmacological release from the naturally occurring polyamine-mediated immune suppression offers profound impact on the immunotherapy of cancer together with a variety of diseases caused by the disease-causing vector's ability to evade an immune reaction. This therapeutic approach is equally applicable to disease states whereby immune system suppression by polyamines has been demonstrated including; bacterial infections, parasitic infections including malaria and typanosomiasis, viral infections, peptic ulcers and gastric cancer due to H. Pylori infection together with prevention of pregnancy. With a small molecule drug, used in combination with DFMO, the pharmacological manipulation of polyamine levels for therapeutic benefit in various disease states is possible.

The invention provides lactobacillus plantarum capable of resisting helicobacter pylori infection and application of the lactobacillus plantarum. The lactobacillus plantarum capable of resisting helicobacter pylori infection is named as lactobacillus plantarum Lp05 and is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC No.23547, and the preservation date is October 9, 2021. The invention also provides a culture method of the lactobacillus plantarum for resisting helicobacter pylori infection and a product for inhibiting helicobacter pylori infection. The lactobacillus plantarum for resisting helicobacter pylori infection is good in gastric acid resistance, proliferation of helicobacter pylori is inhibited, the adhesion effect of helicobacter pylori on gastric epithelial cells is reduced, and conditions are created for eradicating helicobacter pylori. The product for inhibiting helicobacter pylori infection does not cause adverse reaction and drug resistance of pathogenic bacteria, and is high in application value.

The invention discloses a recombinant helicobacter pylori protein vaccine and a preparation method thereof. The active ingredient recombinant fusion protein of the vaccine consists of recombinant LTAl-Ureal protein and LTB protein, the amino acid sequence of the recombinant LTAl-Ureal protein is shown as Seq ID No.1, the amino acid sequence of the LTB protein is shown as Seq ID No.2. Epitope-containing gene segments of Hp urease A subunit is inserted in an LTA subunit-encoded gene, a toxic part-containing segment is replaced to prepare a recombinant plasmid so as to express and obtain recombinant fusion protein polymer as a vaccine antigen, the fusion antigen and LTB protein pentamer are combined to form a hexamer structure, so that not only can the structure basis and activity of an LT mucosa adjuvant be remained, but also the toxicity can be removed, the immune response of organism muscosa can be effectively induced through immunity of mucosa path, to generate specific IgA antibody. The recombinant helicobacter pylori protein vaccine provides a vaccine manner for preventing and treating infection of helicobacter pylori.

Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and / or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine.

This invention provides a B cell epitope peptide and its identification method to neutralize helicobacterpylori urease B subunit, determines the antigen epitope corresponding with the monoclonal antibody 6E6 of helicobacterpylori urease B subunit, and confirms this B cell epitope is specific for the 6E6. The invention also provides a chimeric epitope vaccine and its preparation method containing B cell epitope and carrier protein BSA, and the B cell epitope has strong antigenicity.

The present invention relates to methods for treating pathological conditions associated with Helicobacter sp infections, specifically H. pylori infection. The present invention further relates to methods for treating pathologies characterized by excess gastric acid secretion. The methods of the present invention comprise oral administration of pentagastrin effective locally in the stomach in conjunction with a gastric proton pump inhibitor. It is disclosed herein for the first time that PG administered orally exerts a local effect in the stomach and may be used in combination with a PPI for treating pathological conditions characterized by excess gastric acid secretion and in pathological conditions associated with Helicobacter sp infections.

The present invention provides a pharmaceutical composition for the treatment of disorders induced, caused, and / or mediated by Helicobacter pylori infection, as well as methods of treating the same by administering the pharmaceutical composition of the present invention.

The invention discloses lactobacillus rhamnosus and application thereof in inhibition of helicobacter pylori, and belongs to the technical fields of microorganisms and medicines. The invention provides a lactobacillus rhamnosus strain CCFM1119, and the lactobacillus rhamnosus strain CCFM1119 has the effect of preventing and / or treating helicobacter pylori infection. (1) the lactobacillus rhamnosusstrain CCFM1119 can obviously relieve gastrointestinal symptoms of a patient infected by helicobacter pylori; (2) the lactobacillus rhamnosus strain CCFM1119 can significantly reduce the colonizationamount of helicobacter pylori in the body of a patient infected by helicobacter pylori; and (3) the lactobacillus rhamnosus strain CCFM1119 can significantly improve the removal rate of helicobacterpylori in the body of a patient infected by helicobacter pylori, and thus the lactobacillus rhamnosus strain CCFM1119 has a huge application prospect in the preparation of products (such as foods or medicines) for preventing and / or treating helicobacter pylori infection.

The present invention discloses recombinant vaccine based on the Helicobacter pylori neutral granulocyte activated protein A (NapA) antigen and its preparation process and application in inducing the protecting immune reaction resisting Helicobacter pylori infection. The vaccine consists of independent Helicobacter pylori NapA as the basic active component, or the fusion protein comprising Helicobacter pylori NapA, adhesion HpaA and urase B subunit active segment (UreB414), and one or several kinds of pharmaceutically acceptable adjuvant and excipient.

The invention discloses lactobacillus crispatus capable of preventing and / or treating helicobacter pylori infection, and belongs to the technical field of microorganisms and medicines. The invention provides the lactobacillus crispatus CCFM1118. The lactobacillus crispatus CCFM1118 can inhibit helicobacter pylori, and is specifically characterized in that: (1) the size of an inhibition zone of a lactobacillus crispatus CCFM1118 supernatant on helicobacter pylori can reach 13.14 mm; and (2) the lactobacillus crispatus CCFM1118 can significantly reduce the adhesion of helicobacter pylori to AGScells; therefore, the lactobacillus crispatus CCFM1118 has a huge application prospect in the aspects of inhibiting helicobacter pylori (not aiming at the diagnosis and treatment of diseases) and preparing a helicobacter pylori inhibitor.

Methods of diagnosing Helicobacter pylori infection or associated conditions are based in part on the correlation of the presence of a α-L-fucosidase 2 marker with the infection. Methods and compositions for treating or preventing Helicobacter pylori infection or associated conditions are based in part on administering an α-L-fucosidase 2 inhibitor to an infected subject or a subject at risk of developing the infection.

The invention discloses a traditional Chinese medicine for treating chronic gastritis caused by deficiency cold in spleen and stomach and a preparation method of the traditional Chinese medicine. The traditional Chinese medicine comprises the following raw materials: orange peel, agilawood, silverweed cinquefoil root, stichopus japonicas, buckeye, hispid arthraxon, viburnum fordiae, baked ginger, pericarpium arecae, thlaspi arvense, fingered citron, sambucus chinensis, persimmon calyx, white egret flower, starfish, angelica sinensis, rhizoma cyperi, alkaline marin, cynanchum wilfordii, procumbent speedwell, pericarpium citri reticulatae, herba cistanche, fructus psoraleae, castanea seguinii, trifoliate orange, fructus amomi, saccatespur larkspur, sandalwood, prostrate hemlock, fructus piperis longi, zanthoxylum avicennae, poria cocos, lucid ganoderma, radix pseudostellariae, rhizoma atractylodis macrocephalae, primula obconica and cyananthus argernteus marg. The traditional Chinese medicine for treating chronic gastritis caused by deficiency cold in spleen and stomach has the functions of warming middle, invigorating spleen and regulating stomach to relieve pain, is mainly used for treating chronic gastritis caused by deficiency cold in spleen and stomach, is capable of treating treatment based on syndrome differentiation by using the theory of traditional Chinese medicine, is relatively high in pertinence, can be used for treating the same disease with different methods according to the different clinical stages of the diseases and treating different diseases with the same method according to the similar diseases, has the effects of removing helicobacter infections, protecting gastric mucosa, eliminating cold to stop pain and improving overall immunity of the organism, and has the advantages of being quick in effect, high in effective rate, obvious in curative effect, short in treatment course, free of toxic and side effects and low cost.

The invention relates to rabeprazole sodium for injection as well as a preparation method and a detection method thereof. The rabeprazole sodium for injection is a medical preparation for injection, which is prepared from rabeprazole sodium as an active ingredient, a stabilizing agent, a pH value regulator and pharmaceutically acceptable auxiliary materials. The rabeprazole sodium for injection, disclosed by the invention, is rapid in effect taking and high in bioavailability, is used for treating gastrohelcosis, duodenal ulcer, erosive gastroesophageal reflux disease, helicobacter pylori injection, Zollinger-Ellision syndrome and the like and is more suitable for being used as a substitutive medicament when oral preparations for treating the diseases have no effect.

The invention discloses an intramolecular adjuvant-containing recombinant gene for preventing and treating helicobacter pylori, protein and a biological product. the multi-target recombinant gene comprises a multi-target fusion polypeptide having an amino acid sequence shown in a SEQ ID NO:2, a multi-target recombinant gene for coding the multi-target fusion polypeptide having the nucleotide sequence shown in a SEQ ID NO:2, and invention also has an application of a specific antibody of the above multi-target recombinant gene or the above multi-target fusion polypeptide or the multi-target fusion polypeptide as the biological product for preventing and treating helicobacter pylori infection. According to the invention, an intramolecular adjuvant CTB for removing signal peptide is added at N segment of a recombinant helicobacter pylori multi-target fusion polypeptide (rIB), so that prevention and treatment effect for the helicobacter pylori infection can be increased.

The invention discloses a chemical medicine composition for treating helicobacter pylori (Hp) infection of adults through oral administration. The composition at least comprises fosfomycin or pharmaceutical salts such as a sodium salt, a calcium salt, fosfomycin trometamol and aminoglycoside medicines of the fosfomycin of a common dosage of an adult, and the aminoglycoside medicines are selected from tobramycin, netilmicin, etimicin, isepamicin, amikacin and common salts such as sulfate, of the medicines.

The invention discloses a composition for resisting helicobacter pylori and the application of the composition. The composition comprises linolenic acid capsules, a zinc preparation (zinc gluconate orpolaprezinc) and a proton pump inhibitor. The pharmaceutical composition can inhibit helicobacter pylori in vivo and in vitro by combined use, has a good effect on treatment of gastritis and other related diseases caused by helicobacter pylori infection, and especially has a good effect on refractory gastritis caused by drug-resistant helicobacter pylori infection. According to the composition, helicobacter pylori infection can be cured under the condition that antibiotics are not used, the cure rate is increased, and the occurrence rate of antibiotic resistance is reduced.

The present invention relates to the new use of acidophilic lactobacillus in preparing functional food and medicine, and is especially health article and medicine for preventing and treating chronic gastropathy prepared with acidophilic lactobacillus. Acidophilic lactobacillus with specific pyloric helicobacter antagonizing effect is cultured, separated and screened from human gastrointestinal tract excrement, and inoculated to food or medicine acceptable carrier. The acidophilic lactobacillus has the specific pyloric helicobacter antagonizing characteristics of bacteriostasis ring diameter detected via agar perforating process greater than 2 cm, pyloric helicobacter urease inhibiting activity in 2 hr greater than 50 % and 4 hr inhibition of pyloric helicobacter growth greater than 1 LgCFU / ml. Taking the health article or medicine of the present invention can preventing and treating chronic gastropathy caused by pyloric helicobacter infection.

Compositions and methods for treating, preventing and diagnosing Helicobacter infection are disclosed. The methods use proteins and / or nucleic acids derived from Helicobacter cerdo, a new pathogen isolated from swine. In addition, porcine models for studying bacterial gastritis and gastric and duodenal ulcer disease caused by Helicobacter pathogens, such as H. pylori and H. cerdo are described, as well as methods of identifying vaccines and compounds for treating and / or preventing Helicobacter infection using the animal models. Also described are methods of preventing Helicobacter infection in swine, such as infection caused by H. cerdo, using immunogenic proteins and nucleic acids derived from Helicobacter pathogens, such as H. pylori.

A sterile immunogenic preparation of three purified H. pylori antigens (CagA, VacA and NAP) adjuvanted with alum in an isotonic buffer solution for intramuscular injection. The antigens may be administered in conjunction with antibiotics and / or antisecretories. Urease breath testing, stool antigen testing, and / or immunological analysis may be used as correlate(s) of protection against H. pylori infection. Urea may be used to improve VacA solubility.

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with Helicobacter pylori, in particular H. pylori infection and gastroduodenal disorders caused by H. pylori. The present invention further relates to methods of detecting H. pylori infection in a subject.

The invention discloses a recombinant helicobacter pylori multi-epitope tandem vaccine and a preparation method thereof. The vaccine is composed of an escherichia coli labile toxin B subunit (LTB) andepitopes selected from helicobacter pylori antigens HpaA, UreB and CAT. The helicobacter pylori multi-tandem epitope vaccine can generate a high-titer antibody sIgA and a specific IgG antibody in serum in gastric mucosa, and the specific antibody IgG can significantly inhibit helicobacter pylori urease activity. The vaccine can be used for preventing or treating helicobacter pylori infection.

The invention discloses lactobacillus reuteri capable of resisting helicobacter pylori infection and application of the lactobacillus reuteri. The lactobacillus reuteri is identified as lactobacillus reuteri, the strain name is DRTR, the lactobacillus reuteri is preserved in the China Center for Type Culture Collection, the preservation date is October 19, 2020, and the preservation number is CCTCC NO: M2020597. The lactobacillus reuteri provided by the invention has good gastric acid resistance, can inhibit proliferation of helicobacter pylori and urease activity, and reduces adhesion of the helicobacter pylori to human gastric mucosa cells GES-1; the helicobacter pylori is prepared into a corresponding product for inhibiting helicobacter pylori infection, so that the growth of helicobacter pylori in a stomach environment can be inhibited; when the compound is combined with antibiotics to treat helicobacter pylori infection, the eradication rate can be remarkably increased, side effects in the treatment process are reduced, and the compound has very high application value.

The invention belongs to the field of medical data mining, and particularly relates to a helicobacter pylori stomach video full-automatic intelligent analysis system and a marking method thereof.The helicobacter pylori stomach video full-automatic intelligent analysis system comprises an image acquisition module, an image preprocessing module, an effective frame module, an anatomical position positioning module, a deep learning module and a mark display module; the image preprocessing module is used for preprocessing images of a video stream, the effective frame module is used for classifying and screening the images of the video stream, and the anatomical position positioning module is used for identifying the specific position of an endoscope in the stomach currently. And the deep learning module is used for predicting the helicobacter pylori infection probability for the pictures of different anatomical positions. In the testing process, a doctor does not need to step on a pedal to input a specific picture for helicobacter pylori infection recognition, manual intervention is not needed in the whole process, and full automation and high intelligence can be achieved.

The invention provides an egg yolk antibody composition and an application thereof in preparation of a product for preventing and treating gastrointestinal diseases. The egg yolk antibody compositioncomprises a helicobacter pylori serine protease egg yolk antibody, a helicobacter pylori outer membrane protein egg yolk antibody, a helicobacter pylori whole-bacterium egg yolk antibody and a helicobacter pylori broken bacterium egg yolk antibody. The four egg yolk antibodies are compounded, the binding titer of the obtained compound egg yolk antibody and helicobacter pylori is far higher than that of any single egg yolk antibody, the obvious helicobacter pylori infection resisting effect is achieved, and the compound egg yolk antibody can be further applied to various products and can effectively prevent and treat diseases related to helicobacter pylori infection.

The invention discloses a probiotic agent PAPCH for preventing and treating helicobacter pylori infection and a preparation method of the probiotic agent PAPCH. The probiotic agent PAPCH comprises lactobacillus casei lyT-7 and a protective agent, The preservation number of the lactobacillus casei lyT-7 is CCTCC NO: M 2010197, the preservation time is August 9th, 2010, and the preservation addressis China Center for Type Culture Collection (CCTCC). The addition quantity of the protective agent is 50-150wt% of the use quantity of the lactobacillus casei lyT-7. The prepared probiotic agent can effectively inhibit adhesion of the helicobacter pylori on gastric epithelial cells, inflammatory reaction and immune response caused by the helicobacter pylori, and oxidation reaction induced by helicobacter pylori infection, can directly inhibit and even kill the helicobacter pylori, besides, can improve the micro-ecological environment of gastrointestinal tracts, and can reduce adverse effects of antibiotics.